Top Page
Dimerix Limited
(Sydney:DXB)
Dimerix Limited (DXB) vs. iShares MSCI Australia ETF (EWA)
Dimerix Limited Business Overview & Revenue Model
Dimerix Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.59M | 1.25M | 583.48K | 36.79K | 6.46M | 4.44M |
| Gross Profit | 5.59M | 1.25M | 583.48K | 36.79K | 6.41M | 4.39M |
| EBITDA | -31.67M | -36.22M | -24.96M | -22.68M | -16.47M | -10.02M |
| Net Income | -13.25M | -13.25M | -17.07M | -13.80M | -10.49M | -6.37M |
Balance Sheet | ||||||
| Total Assets | 91.18M | 91.18M | 32.08M | 17.76M | 16.50M | 9.42M |
| Cash, Cash Equivalents and Short-Term Investments | 68.28M | 68.28M | 22.14M | 7.99M | 9.63M | 5.25M |
| Total Debt | 97.48K | 97.48K | 149.68K | 5.96M | 73.10K | 5.09M |
| Total Liabilities | 77.80M | 77.80M | 13.89M | 11.79M | 2.07M | 7.95M |
| Stockholders Equity | 13.38M | 13.38M | 18.19M | 5.96M | 14.42M | 1.47M |
Cash Flow | ||||||
| Free Cash Flow | 39.03M | 39.03M | -7.02M | -12.73M | -13.45M | -6.47M |
| Operating Cash Flow | 39.05M | 39.05M | -7.00M | -12.73M | -13.44M | -6.46M |
| Investing Cash Flow | -21.01K | -21.01K | -15.80K | -2.30K | -10.61K | 4.38K |
| Financing Cash Flow | 7.42M | 7.42M | 21.17M | 11.07M | 17.69M | 3.83M |
Dimerix Limited Technical Analysis
Dimerix Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$664.16M | 18.31 | 15.90% | 0.38% | 7.76% | 1.55% | |
54 Neutral | AU$489.93M | -98.55 | -27.89% | ― | ― | 67.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$582.12M | -9.36 | -35.86% | ― | ― | -19.21% | |
47 Neutral | AU$336.22M | -23.53 | -83.97% | ― | 1271.12% | 36.87% | |
41 Neutral | AU$290.07M | -29.81 | -89.70% | ― | 42.05% | -0.84% | |
40 Underperform | AU$91.29M | -11.18 | -47.98% | ― | 700.00% | 26.88% |
Dimerix Limited Corporate Events
Dimerix Limited announced the successful completion of the seventh Independent Data Monitoring Committee (IDMC) review of its ACTION3 Phase 3 FSGS kidney trial, with no safety concerns raised. This endorsement supports the strong safety profile of DMX-200, positioning it as a promising treatment option in the FSGS landscape, offering hope to patients with limited options and representing a significant commercial opportunity in an underserved market.
Dimerix Limited announced that all resolutions at its 2025 Annual General Meeting were passed with the required majorities. Key resolutions included the re-election of Dr. Sonia Poli as a director and the approval of a 10% placement capacity under ASX Listing Rule 7.1a. The successful passing of these resolutions supports Dimerix’s strategic initiatives and strengthens its governance structure, potentially enhancing its market position and stakeholder confidence.
Dimerix Limited has made significant progress in the 2024-25 financial year by advancing its lead program, DMX-200, through the Phase 3 ACTION3 clinical trial for focal segmental glomerulosclerosis (FSGS), a condition with no approved therapies. The company has nearly completed patient recruitment and has entered into four commercial licensing agreements valued at up to $1.4 billion, which provide non-dilutive capital and de-risk development. These efforts position Dimerix for potential market approval and significant commercial opportunities, particularly in high-need markets, while also strengthening its operational and scientific credibility.
Dimerix Limited announced significant progress in its quarterly activities report, highlighting the advancement of its DMX-200 product candidate in the ACTION3 Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS). The company received Orphan Drug Designation in Japan and reported a strong cash position of AU$49.2 million. The successful data analysis from the PARASOL collaboration is expected to support potential marketing approval for DMX-200 globally. Despite a net operating cash outflow of AU$18.8 million, Dimerix anticipates reduced cash outflows in future quarters as the trial nears full recruitment, maintaining a focus on licensing opportunities and new R&D pipeline activities.
Dimerix Limited has announced the issuance of 212,170 fully paid ordinary shares following the cashless exercise of 799,500 unlisted options. This move, which was made without disclosure under Part 6D.2 of the Corporations Act 2001, signifies the company’s adherence to regulatory compliance and may impact its market positioning by potentially increasing liquidity and shareholder value.
Dimerix Limited has announced the application for quotation of 212,170 ordinary fully paid securities on the Australian Securities Exchange (ASX), under the code DXB. This move is part of an employee incentive scheme, indicating the company’s efforts to motivate and retain talent, which could positively impact its operational capabilities and market positioning.
Dimerix Limited announced that its CEO, Dr. Nina Webster, will present at the Canaccord Drug & Device Conference 2025, highlighting the status of their Phase 3 global clinical trial for FSGS kidney disease and commercial partnering efforts. This presentation underscores Dimerix’s commitment to advancing DMX-200, a promising treatment for FSGS, a rare kidney disorder with limited treatment options, potentially enhancing their market positioning and offering hope for patients with unmet medical needs.
Dimerix Limited has announced the details for its 2025 Annual General Meeting (AGM), which will be held in person at its office in Fitzroy, Victoria. The company has made available the Notice of Meeting and Proxy Form online, emphasizing the importance of shareholder engagement and participation in the upcoming meeting. This announcement reflects Dimerix’s commitment to transparency and effective communication with its stakeholders, as it continues to advance its clinical programs and strengthen its position in the biopharmaceutical industry.
Dimerix Limited announced the successful completion of a data analysis by the PARASOL collaboration, which supports the use of proteinuria endpoints in their ACTION3 study for potential marketing approval in the US. The analysis observed a potential relationship between proteinuria at 12 months and the risk of kidney failure, which will be discussed with the FDA for possible accelerated approval pathways. This development could significantly impact Dimerix’s operations and industry positioning by potentially expediting the approval process for their kidney disease treatment, thereby benefiting stakeholders.
Dimerix Limited announced that its lead asset, DMX-200, has received Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. This designation provides significant benefits such as financial incentives, regulatory assistance, and market exclusivity, enhancing the commercial potential of DMX-200. The Phase 3 clinical trial, ACTION3, is currently recruiting in Japan, and Dimerix’s commercial partner, FUSO Pharmaceutical Industries, has exclusive rights to develop and commercialize DMX-200 in Japan. The designation marks a major milestone for Dimerix’s global strategy to provide new treatment options for FSGS patients.
Dimerix Limited has announced that its Annual General Meeting (AGM) will take place on 18 November 2025 at its office in Fitzroy, Victoria. The meeting will include an update from CEO Dr. Nina Webster, and the deadline for director nominations is set for 30 September 2025. This announcement is significant for stakeholders as it provides an opportunity for shareholders to receive updates on the company’s progress and strategic direction, particularly regarding its Phase 3 clinical developments.